Guselkumab (Tremfya, Johnson & Johnson) demonstrated improvement in axial symptoms and reduction in inflammation by magnetic resonance imaging (MRI) assessment in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA), according to top-line results from the Phase 4 STAR study.
STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an interleukin (IL)-23 inhibitor specifically in patients with axial involvement confirmed by MRI. These top-line findings will be presented at an upcoming scientific congress.
In the STAR study, guselkumab met the primary endpoint evaluating improvement in a composite patient-reported disease activity score that includes spinal pain, stiffness, fatigue, joint symptoms, and areas of tenderness (the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]) at Week 24 vs. placebo. Guselkumab also met major secondary endpoints demonstrating a significant reduction in both axial symptoms, as measured by Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP), and objective (MRI) inflammation of the sacroiliac joints. The overall safety profile observed in the STAR study was consistent with the established safety profile of guselkumab in PsA, and no new safety signals were identified.
“Clinical data continue to expand the evidence base for TREMFYA effectiveness across multiple domains of psoriatic arthritis,” says Philip J. Mease, MD, MACR, FRCP, Director of Rheumatology Research at the Providence Swedish Medical Center and Clinical Professor at the University of Washington School of Medicine in Seattle, WA, in a news release. “What makes the STAR study particularly noteworthy is that, for the first time in a prospective, randomized, double-blinded, placebo-controlled PsA study, it evaluates MRI assessments for inclusion and provides a rigorous and objective measure of improvements in inflammation alongside clinical outcomes in axial PsA. Together, these findings contribute to a more comprehensive understanding of disease activity and treatment effects.”
STAR is a Phase 4, multicenter, randomized, double-blind, placebo-controlled study evaluating guselkumab in biologic-naïve adults with active PsA and axial involvement. Eligible participants had active PsA with objective evidence of axial inflammation confirmed by centrally read MRI and elevated C-reactive protein despite previous treatment with non-biologic disease-modifying antirheumatic drugs (DMARDs), apremilast, and/or nonsteroidal anti-inflammatory drugs (NSAIDs).
The study enrolled 411 participants worldwide and included a 24-week placebo-controlled treatment period followed by a 24-week active treatment period. The primary endpoint evaluated change from baseline in BASDAI at Week 24. Secondary endpoints included additional assessments of axial symptoms, MRI inflammation, physical function, peripheral musculoskeletal manifestations, skin disease, and safety.
Johnson & Johnson recently received US Food and Drug Administration (FDA) approval of a label expansion for the inhibition of progression of structural joint damage in adults with active PsA.